Ubs Oconnor LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.55 - $1.26 $216,686 - $496,408	393,975 New	393,975 $277 Million
Q1 2023 May 15, 2023	SELL	$0.89 - $2.52 $44,500 - $126,000	-50,000 Reduced 10.59%	422,102 $379,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $255,062 - $1.87 Million	250,061 Added 112.62%	472,102 $0
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $496,844 - $794,621	-82,259 Reduced 27.03%	222,041 $1.67 Billion
Q2 2022 Aug 12, 2022	BUY	$4.99 - $8.96 $769,957 - $1.38 Million	154,300 Added 102.87%	304,300 $1.92 Million

Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $378,624 - $960,364	98,600 Added 191.83%	150,000 $1.25 Million
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $492,926 - $616,800	51,400 New	51,400 $526,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.